Last $64.17 USD
Change Today -0.22 / -0.34%
Volume 1.4M
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
GlobeNewswire  02/21/2014 9:02 PM ET
INTERCEPT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. -- ICPT

NEW ORLEANS, Feb. 21, 2014 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 22, 2014 to file lead plaintiff applications in a securities class action lawsuit against Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), if they purchased the Company's securities during the period between January 9, 2014 and January 10, 2014, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.

What You May Do

If you purchased shares of Intercept and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850, or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com) or KSF Partner Melinda Nicholson (melinda.nicholson@ksfcounsel.com). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 22, 2014.

About the Lawsuit

Intercept and certain of its executives are charged with issuing a series of materially false and misleading statements during the Class Period, violating federal securities laws.

On January 9 and 10, 2014, Intercept announced that its Phase 2 trial of its primary drug compound obeticholic acid had been stopped early based on an interim analysis that showed that the efficacy endpoint of the trial had been met.

Then, on Friday, January 10, 2014, after the markets closed, the National Institutes of Health issued a written statement revealing that, while the efficacy primary endpoint in the study had already been met, participants in the study who received the drug suffered disproportionate levels of lipid abnormalities. On this news, Intercept's stock price plummeted.

About Kahn Swick & Foti, LLC

To learn more about KSF, whose partners include the Former Louisiana Attorney General, Charles C. Foti, Jr., and other lawyers with significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders, you may visit www.ksfcounsel.com.

CONTACT: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner lewis.kahn@ksfcounsel.com Melinda Nicholson, Partner melinda.nicholson@ksfcounsel.com 1-877-515-1850 206 Covington St. Madisonville, LA 70447

Source: Kahn Swick & Foti, LLC
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRTX:US $64.17 USD -0.22

Industry News

Court declines to block drug ruling in patent case
Court declines to block drug ruling in patent case
Business events scheduled for the coming week

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.